InCarda Therapeutics
PrivateLast Round
Series D
Jun 15, 2022
Total Funding Raised
$77.56M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
InCarda Therapeutics is a biopharmaceutical company that develops innovative inhaled therapies for the targeted treatment of cardiovascular conditions, including paroxysmal atrial fibrillation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
InCarda Therapeutics Comparables
Compare InCarda Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HUYA Bioscience International | 78% | |
| Acesion Pharma | 77% | |
| Philip Morris International | 73% |
InCarda Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jun 15, 2022 | ||||
| Series C | Oct 21, 2020 | ||||
| Series B | Nov 8, 2018 | ||||
| Series A | Apr 28, 2015 | ||||
| Private Placement | Dec 5, 2014 | ||||
Debt | Aug 28, 2013 |
Key People
Founding team and executive leadership
InCarda Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series B, Series C |
| Morningside Ventures | Series B, Series C, Series A |
| Innoviva | Series D, Series C |
| Asset Management Ventures | Series B |
| HealthCap | Series C, Series B |
| Morningside Group | Series B, Series C, Series A |
| Sofinnova Investments | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 117% MoM.
- Jun 18, 2026
Monthly visitors grew 39% MoM.
InCarda Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about InCarda Therapeutics's valuation, stock price, and market status.
Is InCarda Therapeutics a public or private company?
InCarda Therapeutics is a private company.
What is the current stock price of InCarda Therapeutics?
InCarda Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is InCarda Therapeutics worth (valuation)?
Valuation information for InCarda Therapeutics is not publicly available.
Can I buy InCarda Therapeutics stock?
InCarda Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was InCarda Therapeutics's last funding round?
InCarda Therapeutics's most recent funding round was Series D on June 15, 2022.
Who are the main investors in InCarda Therapeutics?
Key investors in InCarda Therapeutics include Innoviva, HealthCap, Sofinnova Investments.
Will InCarda Therapeutics IPO soon?
No public IPO plans have been announced for InCarda Therapeutics.
How can I track InCarda Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor InCarda Therapeutics's secondary market activity and sign up for updates.